Neurocrine Biosciences target price raised to $220 from $210 by Canaccord Genuity
NBIX•Canaccord Genuity raised its target price for Neurocrine Biosciences to $220 from $210.
Related News
Garanti BBVA completes sale of Romanian subsidiary for €571 million
BBVA•
Nasdaq trade halt continues; reason not available at 03:58 am
MCTA•
East West Bancorp: Barclays raises target price to $160 from $155
EWBC•
GlobalWafers board approves up to $500 million convertible bond sale to Micron
MU•
HSBC files HKEX next-day disclosure return on share buyback, cancellation
HSBC•